Rosuvastatin Calcium
FDA-approved product (tablet, oral), marketed as Crestor, Ezallor Sprinkle, Rosuvastatin Calcium.
- Registered studies
- 50+
- Lab records
- 0
- Pathogens at ≥40%
- 2 of 4
Chemical structure
Existing / approved use
Documented · FDA, WHO, ChEMBLApproved for
- Atherosclerosis
- Cardiovascular disease
- Coronary artery disease
- Familial hypercholesterolemia
- Hypercholesterolemia
- Hyperlipidemia
- Hyperlipoproteinemia type 3
Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗
- WHO therapeutic group
- Hmg coa reductase inhibitors
- Anti-infective classification
- Not classified as an anti-infective.
Repurposing investigation
This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.
AI-predicted activity
AI prediction · nothing measured- MRSA43.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- E. coli35.9% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- K. pneumoniae24.3% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- M. tuberculosis63.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.
Evidence
Clinical and experimental
Documented evidenceClinical
50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.
Experimental
No evidence found
No laboratory measurement against the four pathogens in the ChEMBL records loaded here.
Docking
Computational · nothing measuredDihydrofolate reductase ↗ (E. coli)
Not yet docked: queued in the docking rundetails
KPC-2 carbapenemase ↗ (K. pneumoniae)
Not yet docked: queued in the docking rundetails
Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)
Not yet docked: queued in the docking rundetails
Dihydrofolate reductase ↗ (MRSA)
Not yet docked: queued in the docking rundetails
AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.
Other medicines to investigate
AI prediction · nothing measuredOther repurposing candidates: approved medicines besides Rosuvastatin Calcium with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.
Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.
- Etrasimod ArginineExisting use: Ulcerative colitis64.1% AI-predicted activityagainst MRSANo documented evidence found
- MethotrexateExisting use: Acute lymphoblastic leukemia, Adenoma, Arthritis and 21 more64.1% AI-predicted activityagainst MRSA50+ registered studies
- KetoconazoleExisting use: Adrenal gland disease, Blastomycosis, Cushing syndrome and 3 more63.6% AI-predicted activityagainst MRSA50+ registered studies
- LevoketoconazoleExisting use: Adrenal gland disease, Adrenal gland hyperfunction, Cushing syndrome63.6% AI-predicted activityagainst MRSA6 registered studies
- Nafarelin AcetateExisting use: Endometriosis63.6% AI-predicted activityagainst MRSA12 registered studies
- Pafolacianine SodiumExisting use: Other diagnostic agents63.6% AI-predicted activityagainst MRSA1 registered study
- Vinorelbine TartrateExisting use: Cancer, Neoplasm63.6% AI-predicted activityagainst MRSA50+ registered studies
- Ibrexafungerp CitrateExisting use: Vulvovaginal candidiasis63.5% AI-predicted activityagainst MRSANo documented evidence found
- Gonadorelin AcetateExisting use: Gonadotropin-releasing hormones, Tests for fertility disturbances63.4% AI-predicted activityagainst MRSA50+ registered studies
- Icatibant AcetateExisting use: Angioedema, Hereditary angioedema63.4% AI-predicted activityagainst MRSA33 registered studies
- LonafarnibExisting use: Hutchinson-Gilford progeria syndrome, Laminopathies, Progeria63.3% AI-predicted activityagainst MRSA39 registered studies
- LypressinExisting use: Vasopressin and analogues63.2% AI-predicted activityagainst MRSA50+ registered studies
Registered studies
A registration describes a study; it does not establish a positive result.
Phase 1 Clinical Trial to Investigate the Effect on the Pharmacokinetics of YH14755 Compared to Co-administration of Rosuvastatin and Metformin SR in Healthy Volunteers
NCT02125227 · start 2014-04
Registered record
- Registry ID
- NCT02125227
- Conditions
- Healthy
- Interventions
- Rosuvastatin, Metformin, YH14755; YH14755
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- 2014-04
- Completion
- 2014-09
- Enrolment
- 56
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHealthyInterventionRosuvastatin, Metformin, YH14755; YH14755PhasePhase 1Registry statusCompletedEfficacy and Safety of PRC-4016 in Subjects With Mixed Dyslipidemia
NCT01972178 · start 2013-11
Registered record
- Registry ID
- NCT01972178
- Conditions
- Dyslipidemia
- Interventions
- PRC-4016; Placebo; Statins
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Terminated
- Start
- 2013-11
- Completion
- 2014-08
- Enrolment
- 113
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionDyslipidemiaInterventionPRC-4016; Placebo; StatinsPhasePhase 2Registry statusTerminatedEfficacy/Safety of Rosuvastatin+Ezetimibe in High Risk Patients With Primary Hypercholesterolemia/Mixed Dyslipidemia
NCT01420549 · start 2013-03
Registered record
- Registry ID
- NCT01420549
- Conditions
- Hypercholesterolemia; Dyslipidemia
- Interventions
- Rosuvastatin 10 mg + Ezetimibe 10 mg and Rosuvastatin 20 mg + Ezetimibe 10 mg, according to clinical evaluation.; Simvastatin 20 mg + Ezetimibe 10 mg and Simvastatin 40 mg + Ezetimibe 10 mg, according to clinical evaluation.
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2013-03
- Completion
- 2014-11
- Enrolment
- 129
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHypercholesterolemia; DyslipidemiaInterventionRosuvastatin 10 mg + Ezetimibe 10 mg and Rosuvastatin 20 mg + Ezetimibe 10 mg, according to clinical evaluation.; Simvastatin 20 mg + Ezetimibe 10 mg and Simvastatin 40 mg + Ezetimibe 10 mg, according to clinical evaluation.PhasePhase 3Registry statusCompletedRosuvastatin Calcium Bioequivalence Study - Fast
NCT01711749 · start 2013-02-25
Registered record
- Registry ID
- NCT01711749
- Conditions
- Hypercholesterolaemia
- Interventions
- Crestor®; rosuvastatin calcium tablets
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- 2013-02-25
- Completion
- 2013-03-13
- Enrolment
- 60
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHypercholesterolaemiaInterventionCrestor®; rosuvastatin calcium tabletsPhasePhase 1Registry statusCompletedClinical Study for Patients With Hypertension Associated With Dyslipidemia
NCT01764295 · start 2012-09
Registered record
- Registry ID
- NCT01764295
- Conditions
- Hypertension; Dyslipidemia
- Interventions
- DWJ1276; Olmesartan; Rosuvastatin; Placebo
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2012-09
- Completion
- 2013-07
- Enrolment
- 150
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHypertension; DyslipidemiaInterventionDWJ1276; Olmesartan; Rosuvastatin; PlaceboPhasePhase 3Registry statusCompletedStatin for Depression in Patients Undergoing Coronary Artery Bypass Graft
NCT01624857 · start 2012-06
Registered record
- Registry ID
- NCT01624857
- Conditions
- Coronary Heart Disease
- Interventions
- Rosuvastatin; Placebo
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Unknown
- Start
- 2012-06
- Completion
- 2014-06
- Enrolment
- 400
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionCoronary Heart DiseaseInterventionRosuvastatin; PlaceboPhasePhase 3Registry statusUnknownStatin Therapy In Cardiac Surgery
NCT01573143 · start 2011-09
Registered record
- Registry ID
- NCT01573143
- Conditions
- Atrial Fibrillation; Myocardium; Injury
- Interventions
- Rosuvastatin; Placebo
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Completed
- Start
- 2011-09
- Completion
- 2014-09
- Enrolment
- 1,922
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionAtrial Fibrillation; Myocardium; InjuryInterventionRosuvastatin; PlaceboPhasePhase 4Registry statusCompletedA Randomized Trial of Rosuvastatin in Elective Angioplasty to Prevent Contrast-induced Nephropathy (CLEAR-CIN).
NCT02737319 · start 2011-03
Registered record
- Registry ID
- NCT02737319
- Conditions
- Nephropathy
- Interventions
- Rosuvastatin
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Completed
- Start
- 2011-03
- Completion
- 2013-12
- Enrolment
- 493
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionNephropathyInterventionRosuvastatinPhasePhase 4Registry statusCompletedUse of Rosuvastatin in HIV-Infected Subjects to Modulate Cardiovascular Risks
NCT01218802 · start 2011-02
Registered record
- Registry ID
- NCT01218802
- Conditions
- HIV Infections; Heart Disease
- Interventions
- Rosuvastatin 10 mg. daily for 96 weeks; Placebo
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- 2011-02
- Completion
- 2014-05
- Enrolment
- 147
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHIV Infections; Heart DiseaseInterventionRosuvastatin 10 mg. daily for 96 weeks; PlaceboPhasePhase 2Registry statusCompletedEffects of Rosuvastatin on the Immune System in Healthy Volunteers With Normal Cholesterol
NCT01200836 · start 2010-07-01
Registered record
- Registry ID
- NCT01200836
- Conditions
- Healthy Volunteers; Statins; Immune Modulation
- Interventions
- Not recorded
- Study type
- OBSERVATIONAL
- Phase
- Not recorded
- Registry status
- Completed
- Start
- 2010-07-01
- Completion
- 2018-10-04
- Enrolment
- 20
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHealthy Volunteers; Statins; Immune ModulationInterventionNot recordedPhaseNot recordedRegistry statusCompletedThe Endothelium Dysfunction in Patients of Obstructive Sleep Apnea Syndrome
NCT01699126 · start 2010-05
Registered record
- Registry ID
- NCT01699126
- Conditions
- Sleep Apnea, Obstructive
- Interventions
- CPAP; Statin
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Completed
- Start
- 2010-05
- Completion
- 2013-08
- Enrolment
- 46
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionSleep Apnea, ObstructiveInterventionCPAP; StatinPhasePhase 4Registry statusCompletedDrug-drug Interaction Study in Healthy Male Volunteers Following the Administration of Pantoprazole and Rosuvastatin
NCT01146483 · start 2010-04
Registered record
- Registry ID
- NCT01146483
- Conditions
- Drug Interaction Potentiation
- Interventions
- Rosuvastatin, Pantoprazole
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- 2010-04
- Completion
- 2011-12
- Enrolment
- 16
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionDrug Interaction PotentiationInterventionRosuvastatin, PantoprazolePhasePhase 1Registry statusCompletedRosuvastatin in Treating Patients With Stage I or Stage II Colon Cancer That Was Removed By Surgery
NCT01011478 · start 2010-03
Registered record
- Registry ID
- NCT01011478
- Conditions
- Colorectal Cancer; Precancerous Condition
- Interventions
- rosuvastatin; placebo
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Terminated
- Start
- 2010-03
- Completion
- 2015-02
- Enrolment
- 406
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionColorectal Cancer; Precancerous ConditionInterventionrosuvastatin; placeboPhasePhase 3Registry statusTerminatedBio Equivalence Study of Torrent Pharmaceutical Ltd's Rosuvastatin Calcium Tablets Under Fasting Condition.
NCT02962310 · start 2009-10
Registered record
- Registry ID
- NCT02962310
- Conditions
- Healthy Subjects
- Interventions
- Torrent's Rosuvastatin Calcium Tablets 40 mg; Crestor 40 mg Tablets of AstraZeneca LP, USA
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- 2009-10
- Completion
- 2009-11
- Enrolment
- 48
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHealthy SubjectsInterventionTorrent's Rosuvastatin Calcium Tablets 40 mg; Crestor 40 mg Tablets of AstraZeneca LP, USAPhasePhase 1Registry statusCompletedTolerability and Lipid Lowering Effect of Weekly/Biweekly Crestor in Statin Intolerant Patients Treated With Zetia
NCT00972829 · start 2009-09
Registered record
- Registry ID
- NCT00972829
- Conditions
- Hypercholesterolemia
- Interventions
- Rosuvastatin; Ezetimibe
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Unknown
- Start
- 2009-09
- Completion
- 2011-03
- Enrolment
- 30
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHypercholesterolemiaInterventionRosuvastatin; EzetimibePhasePhase 4Registry statusUnknown